Postnatal Acetaminophen and Potential Risk of Autism Spectrum Disorder among Males

Area of Science:

• Neurodevelopmental disorders
• Pediatric pharmacology
• Epidemiology

Background:

• Emerging literature suggests a potential association between postnatal acetaminophen exposure and increased risk of autism spectrum disorder (ASD).
• Acetaminophen (paracetamol) is a widely used analgesic and antipyretic in infants and children.
• Understanding risk factors for ASD is crucial for early intervention and prevention strategies.

Purpose of the Study:

• To investigate the association between postnatal acetaminophen exposure and autism spectrum disorder (ASD) in children.
• To examine gender-specific risks associated with early-life acetaminophen exposure.
• To assess the impact of parental uncertainty regarding acetaminophen dosage on ASD risk.

Main Methods:

• Analysis of a dataset from an internet-based survey of 1515 US children.
• Calculation of adjusted odds ratios (aORs) for postnatal acetaminophen doses before age two and ASD diagnosis.
• Estimation of population attributable fraction (PAF) for acetaminophen exposure and ASD in males.

Main Results:

• Postnatal acetaminophen exposure before age two was significantly associated with ASD in male children (aOR 1.023, p=0.020).
• Parental uncertainty about the number of acetaminophen doses administered before age two was also linked to ASD.
• An estimated 40% of ASD risk among US males could be attributable to postnatal acetaminophen exposure.

Conclusions:

• Postnatal acetaminophen exposure may be a significant contributing factor to the risk of ASD, particularly in males.
• Parental uncertainty in medication management warrants further investigation in the context of neurodevelopmental outcomes.
• These findings highlight the need for careful consideration of acetaminophen use in early childhood.